Treatment News : Simeprevir and Sofosbuvir Achieve High Cure Rates in Hep C Null-Responders

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » March 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

March 11, 2013

Simeprevir and Sofosbuvir Achieve High Cure Rates in Hep C Null-Responders

CROI 2013An interim analysis showed that two second-generation, direct-acting antiviral hepatitis C virus (HCV) therapies simeprevir and sofosbuvir led to high cure rates in people who had previously failed a hep C therapy. Representatives from Janssen Pharmaceuticals announced findings from this Phase IIa open-label COSMOS study at the 20th annual Conference on Retroviruses and Opportunistic Infections (CROI) in Atlanta. In the study, the protease inhibitor simeprevir (TMC435), given once daily along with Gilead Sciences’ investigational nucleotide inhibitor sofosbuvir (GS-7977), with or without ribavirin for 12 and 24 weeks. All 80 study participants had genotype 1 of hep C, mild to moderate liver fibrosis and were prior null-responders to antiviral treatment.  

The study randomly divided the participants into four arms:

  • 15 took simeprevir and sofosbuvir for 24 weeks.
  • 24 took simeprevir, sofosbuvir plus ribavirin for 24 weeks.
  • 15 took simeprevir and sofosbuvir for 12 weeks.
  • 27 took simeprevir, sofosbuvir plus ribavirin for 12 weeks.
In the 24-week arms, 66.7 percent of those taking ribavirin (one patient dropped out of the study because of an adverse event, and another person withdrew consent) and 100 percent of those without ribavirin achieved a sustained virologic response four weeks after completing therapy (SVR4, considered a cure). Among those in the 12-week arms, 96.3 percent of those taking ribavirin and 92.9 percent of those taking the regimen without ribavirin achieved an SVR4.


To read the conference abstract, click here.

Search: simeprevir, sofosbuvir, null-responder, hepatitis C, second-generation direct-acting antiviral, ribavirin, Conference on Retroviruses and Opportunistic Infections, CROI, TMC435, GS-7977.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (2 total)

 
[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Have you ever been diagnosed with diabetes or pre-diabetes?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.